Like many other large global pharmaceutical companies, this industry leader was faced with the challenge of decentralised translation spend and countless suppliers operating under different guidelines.

This common scenario made it difficult to control global spend, leverage important translation assets, reduce cost, innovate and drive the necessary standardisation to ensure quality.

To read more, please download this free white paper.